ReviewTexas Heart Institute journal2019
Carcinoid Heart Disease: Review of Current Knowledge.
Review in Texas Heart Institute journal, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
40 citing papers in PubMed, 73 citations in OpenAlex.
- Article
- From Carcinoid Syndrome to Carcinoid Heart Disease: The Cost of Delayed Cardiac Surveillance.Cureus · 2026Article
- Carcinoid Heart Disease: Surgical Timing, Right Ventricular Risk Stratification and Operative Strategy.Journal of cardiovascular development and disease · 2026Review
- Survival trends in the management of carcinoid heart disease among patients with neuroendocrine neoplasms.Cardio-oncology (London, England) · 2026Article
- Article
- The Clinical Impact of Patent Foramen Ovale in Patients With Carcinoid Heart Disease.JACC. Advances · 2026Article
- Article
- Concomitant carcinoid heart disease and patent foramen ovale: a case report and review of literature.Cardio-oncology (London, England) · 2025Article
- Bilateral carcinoid heart disease secondary to a massive right-to-left shunt through a patent foramen ovale: a case report.European heart journal. Case reports · 2025Article
- Impact of oncologic diseases on outcome in patients with severe isolated tricuspid regurgitation.European journal of clinical investigation · 2025Article
- Article
- Carcinoid Heart Disease.Journal of the advanced practitioner in oncology · 2024Article
- Managing end-stage carcinoid heart disease: A case report and literature review.World journal of gastrointestinal oncology · 2024Article
- Does Telotristat Have a Role in Preventing Carcinoid Heart Disease?International journal of molecular sciences · 2024Article
- Use of perioperative telotristat in a patient with carcinoid heart disease.Endocrinology, diabetes & metabolism case reports · 2024Article
- Carcinoid heart disease: a potentially fatal complication of carcinoid syndrome.BMJ case reports · 2023Article
- Percutaneous transcatheter pulmonary and tricuspid valve replacements in a patient with carcinoid heart disease.European heart journal. Case reports · 2023Article
- An Overview of Circulating Biomarkers in Neuroendocrine Neoplasms: A Clinical Guide.Diagnostics (Basel, Switzerland) · 2023Review
- Late-stage diagnosis of carcinoid heart disease due to lack of access to health care.Cardio-oncology (London, England) · 2023Article
- Carcinoid Heart Disease: A Case Report and Literature Review.Arquivos brasileiros de cardiologia · 2023Review
Corrections and comments
- Commented on by
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Carcinoid heart disease is the collective term for all cardiac manifestations in patients who have carcinoid syndrome. Carcinoid heart disease has a multifactorial pathophysiology, and the right side of the heart is usually involved. Symptoms and signs vary depending upon the affected cardiac components; most typical is right-sided heart failure secondary to diseased tricuspid and pulmonary valves. Despite no single ideal diagnostic test, strong suspicion, coupled with serologic and imaging results, usually enables diagnosis. Advances in imaging, such as speckle-tracking echocardiography and cardiac magnetic resonance, have improved the diagnostic yield. Treatment is challenging, warrants a multidisciplinary approach, and can be medical or surgical depending on the cardiac manifestations. Investigators are exploring the therapeutic use of monoclonal antibodies and new somatostatin analogues. In this review, we cover current knowledge about the pathophysiology, diagnosis, and treatment of carcinoid heart disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.